Skip to main content
. 2025 May 17;20:235. doi: 10.1186/s13023-025-03773-6

Table 2.

Endocrine characteristics of patients with MELAS

Total (49) Juvenile (21) Adult (28)
Height SDS (mean ± SD) –2.0 ± 1.3 –2.1 ± 1.5 –2.0 ± 1.3
Weight SDS (mean ± SD) –2.6 ± 1.6 –2.2 ± 1.5 –3.1 ± 1.5
BMI SDS (mean ± SD) –1.6 ± 1.4 –1.2 ± 1.6 –2.2 ± 1.2
Short stature at diagnosis, no. (%) 22 (44.9%) 10 (47.6%) 12 (42.9%)
Age at diagnosis (mean ± SD, years) 23.0 ± 17.7 8.0 ± 4.3 34.9 ± 14.6
Diabetes, no. (%) 23 (46.9%) 9 (42.9%) 14 (50%)
Median age at diagnosis (range) 26 (12, 50) 14.3 (12, 26) 35.5 (25, 50)
Median HbA1c (range) 7.9 (6.5, 18.5) 6.8 (6.5, 12.1) 9.5 (6.5, 18.5)
Initial treatment, no. (%)
Life style modification 1 (4.3%) 1 (11.1%) 0
Insulin 12 (52.2%) 7 (77.7%) 5 (35.7%)
Sulfonylurea 5 (21.7%) 1 (11.1%) 4 (28.6%)
Metformin 5 (21.7%) 0 5 (35.7%)
Hypoparathyoidism, no. (%) 1 (2%) 0 1 (3.6%)
Age at diagnosis (years) 26 - 26
Calcium/Phosphorus (mg/dL) 7.5/4.8 - 7.2/4.8
PTH (pg/dL) 5.0 - 5.0
Papillary thyroid cancer, no. (%) 5 (10.2%) 0 5 (17.9%)
Age at diagnosis (mean ± SD, years) 34.1 ± 6.9 - 34.1 ± 6.9

BMI, body mass index; HbA1c, hemoglobin A1c; no., number; SD, standard deviation; SDS, standard deviation score